PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PTC Therapeutics reports robust earnings, faces data release delays

PTC Therapeutics demonstrated strong financial performance and revenue growth in Q4 2022, setting a positive trajectory for 2023.
While facing challenges such as data release delays and regulatory engagements, the company's innovative pipeline and commercial successes position it well for future opportunities.
With upcoming data readouts, regulatory discussions, and market expansion initiatives, PTC is poised to navigate challenges and leverage opportunities for continued growth and impact.

PTC Therapeutics achieves record revenue, faces regulatory challenges and growth opportunities

PTC Therapeutics reported strong financial performance in Q1 2023, with a clear path towards achieving revenue targets. While facing challenges such as regulatory interactions and data expectations, the company is leveraging opportunities in upcoming study results and strategic initiatives to drive growth and market differentiation.

PTC Therapeutics reports strong Q2 revenue and advances pipeline

PTC Therapeutics showcased robust financial performance, positive trial outcomes, and strategic cost-saving measures in Q2 2023.
The company's strong revenue growth, global expansion plans, and pipeline advancements position it for sustained success.
Challenges include addressing analyst inquiries, navigating regulatory pathways, and ensuring market access post-2024.
Opportunities in product launches, regulatory activities, and strategic partnerships offer avenues for continued growth and innovation.

PTC Therapeutics reports robust Q3 earnings and strategic growth plans

PTC Therapeutics demonstrated strong financial performance and strategic partnerships in Q3 2023 earnings call.
The company's focus on pipeline advancement, commercial growth, and regulatory strategies positions it for future success.
While facing challenges in regulatory compliance and product comparability, PTC Therapeutics is leveraging opportunities for revenue growth and market expansion.

PTC Therapeutics posts robust Q4 earnings amidst regulatory challenges

PTC Therapeutics delivered strong financial performance in Q4 2023, driven by revenue growth and transformative gene therapy results, despite challenges from the CHMP opinion.
The company's strengths lie in its solid balance sheet, positive community feedback, and FDA alignment on registration programs, positioning it for future growth and approvals.
Opportunities abound in the launch of sepiapterin, accelerated approval discussions with the FDA, and promising programs for FA and ALS, signaling a positive outlook for PTC.

PTC Therapeutics reports robust Q1 performance amidst regulatory milestones

PTC Therapeutics demonstrated strong financial and operational performance in Q1 2024, driven by revenue growth and regulatory progress.
While facing challenges such as delays in European market access and regulatory complexities, the company remains focused on key therapeutic advancements.
Opportunities lie in upcoming clinical results, potential market expansions, and strategic regulatory pathways for accelerated product approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

PTC Therapeutics (NASDAQ:PTCT ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Kylie O'Keefe - Senior Vice President, Head of Global Commercial & Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating Officer Eric Pauwels - Chief Business Officer Emily Hill - Chief Financial Officer Conference Call Participants Eric Joseph - JPMorgan Raju Prasad - William Blair Kristen Kluska - Cantor Fitzgerald Joe Thome - Cowen & Company Tazeen Ahmad - Bank of America Alex Xenakis - Truist Securities Stephen Mallon - RBC Capital Alexander Nackenoff - Raymond James Operator Good day and thank you for standing by. Welcome to the PTC Second Quarter 2022 Financial Results and Corporate Update Conference Call.

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz On Q2 2022 Results - Earnings Call Transcript

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -27.54% and 13.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Reports Q2 Loss, Tops Revenue Estimates

- Total revenue of $166 million, representing 42% year-over-year growth –  - Upstaza™ gene therapy granted marketing authorization by European Commission for treatment of AADC deficiency with first commercial patient treated – SOUTH PLAINFIELD, N.J. , Aug. 4, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2022.

PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

SOUTH PLAINFIELD, N.J. , July 21, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2022 financial results and provide an update on the company's business and outlook on Thursday, Aug. 4, at 4:30 p.m.

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results

- PTC Therapeutics to launch first gene therapy directly administered into the brain - SOUTH PLAINFIELD, N.J. , July 20, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Upstaza™ (eladocagene exuparvovec) was granted marketing authorization by the European Commission.

Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency

Los Angeles, California--(Newsfile Corp. - June 24, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ: PTCT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to...

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm

SOUTH PLAINFIELD, N.J. , June 20, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21 st at 8:00 a.m.

PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J. , June 9, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors.

Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors

SOUTH PLAINFIELD, N.J. , June 6, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the William Blair 42nd Annual Growth Stock Conference on Thursday, June 9 at 2:20 p.m.

PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference

- Results highlight strength of PTC Therapeutics' scientific platform in targeting difficult-to-treat rare cancer types - SOUTH PLAINFIELD, N.J. , June 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced encouraging preliminary safety and efficacy results from its Phase 1B study of unesbulin (PTC596) in advanced leiomyosarcoma (LMS) patients.

Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

- Evrysdi is the first and only at-home administered treatment for patients living with SMA - - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date - SOUTH PLAINFIELD, N.J. , May 31, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi ®  (risdiplam) to include infants under 2 months old with spinal muscular atrophy (SMA).

FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old

– First ever gene therapy directly administered into the brain – – Recommended for regulatory approval by EMA – – Results demonstrated sustained improvements in motor and cognitive function – – Conference call scheduled for Monday, May 23, at 8 a.m. ET – SOUTH PLAINFIELD, N.J.

PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

Start Time: 16:30 January 1, 0000 5:36 PM ET PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q1 2022 Earnings Conference Call May 03, 2022, 16:30 PM ET Company Participants Stuart Peltz - Founder and CEO Matthew Klein - COO Eric Pauwels - Chief Business Officer Emily Hill - CFO Kylie O'Keefe - SVP, Global Commercial and Corporate Strategy Conference Call Participants Eric Joseph - JPMorgan Rick Krause - Cantor Fitzgerald Brian Abrahams - RBC Capital Markets Joseph Thome - Cowen and Company Gena Wang - Barclays Robyn Karnauskas - Truist Securities Alex Sklar - Raymond James Colin Bristow - UBS Operator Ladies and gentlemen, thank you for standing by. Welcome to the PTC First Quarter 2022 Financial Results Conference Call.

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q1 2022 Results - Earnings Call Transcript

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know

SOUTH PLAINFIELD, N.J. , April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tuesday, May 3, at 4:30 p.m.

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results

- CHMP Opinion Now Expected May 2022 - SOUTH PLAINFIELD, N.J. , April 14, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) with the Committee for Advanced Therapies (CAT).

PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program

PTC Therapeutics has been cooperating with Roche since 2011.

PTC Therapeutics: One Of The Leaders In The Treatment Of Rare Diseases

PTC Therapeutics (PTCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

PTC Therapeutics (PTCT) Soars 11.1%: Is Further Upside Left in the Stock?

SOUTH PLAINFIELD, N.J. , March 30, 2022  /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington's disease (HD).

PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease

New York, New York--(Newsfile Corp. - March 22, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own PTCT please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. The...

Moore Kuehn, PLLC Encourages Investors of PTC Therapeutics, Inc. To Contact Law Firm

SOUTH PLAINFIELD, N.J., March 11, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in Duchenne muscular dystrophy (DMD) at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 13-16 in Nashville, Tenn.

PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q4 2021 Results - Earnings Call Transcript

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

SOUTH PLAINFIELD, N.J., Feb. 22, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2021.

News for PTC Therapeutics Stock (PTCT)